These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 25457020)

  • 1. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.
    Caffo O; De Giorgi U; Fratino L; Alesini D; Zagonel V; Facchini G; Gasparro D; Ortega C; Tucci M; Verderame F; Campadelli E; Lo Re G; Procopio G; Sabbatini R; Donini M; Morelli F; Sartori D; Zucali P; Carrozza F; D'Angelo A; Vicario G; Massari F; Santini D; Sava T; Messina C; Fornarini G; La Torre L; Ricotta R; Aieta M; Mucciarini C; Zustovich F; Macrini S; Burgio SL; Santarossa S; D'Aniello C; Basso U; Tarasconi S; Cortesi E; Buttigliero C; Ruatta F; Veccia A; Conteduca V; Maines F; Galligioni E
    Eur Urol; 2015 Jul; 68(1):147-53. PubMed ID: 25457020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
    Thomsen FB; Røder MA; Rathenborg P; Brasso K; Borre M; Iversen P
    Scand J Urol; 2014 Jun; 48(3):268-75. PubMed ID: 24255983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
    Zhang T; Dhawan MS; Healy P; George DJ; Harrison MR; Oldan J; Chin B; Armstrong AJ
    Clin Genitourin Cancer; 2015 Aug; 13(4):392-399. PubMed ID: 25708161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.
    Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Med Oncol; 2017 Nov; 34(12):200. PubMed ID: 29164346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
    Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G
    Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.
    Papazoglou D; Wannesson L; Berthold D; Cathomas R; Gillessen S; Rothermundt C; Hasler L; Winterhalder R; Barth A; Mingrone W; Nussbaum CU; von Rohr L; von Burg P; Schmid M; Richner J; Baumann S; Kühne R; Stenner F; Rothschild SI
    Clin Genitourin Cancer; 2017 Jun; 15(3):e315-e323. PubMed ID: 27450512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
    Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Urol Oncol; 2017 Jun; 35(6):432-437. PubMed ID: 28188090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.
    Okita K; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Ito A; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
    Clin Genitourin Cancer; 2020 Apr; 18(2):e103-e111. PubMed ID: 31810867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
    Puente J; González-Del-Alba A; Sala-Gonzalez N; Méndez-Vidal MJ; Pinto A; Rodríguez Á; Cuevas Sanz JM; Muñoz Del Toro JR; Useros Rodríguez E; García García-Porrero Á; Vázquez S
    BMC Cancer; 2019 Aug; 19(1):766. PubMed ID: 31382926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
    Oh WK; Miao R; Vekeman F; Sung J; Cheng WY; Gauthier-Loiselle M; Dhawan R; Duh MS
    Med Oncol; 2017 Aug; 34(9):160. PubMed ID: 28795333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
    Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1073-e1080. PubMed ID: 28826931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
    Nadal R; Zhang Z; Rahman H; Schweizer MT; Denmeade SR; Paller CJ; Carducci MA; Eisenberger MA; Antonarakis ES
    Prostate; 2014 Nov; 74(15):1560-8. PubMed ID: 25176007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
    Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S
    Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.
    Caffo O; Wissing M; Bianchini D; Bergman A; Thomsen FB; Schmid S; Yu EY; Bournakis E; Sella A; Zagonel V; De Giorgi U; Tucci M; Gelderblom H; Galli L; Pappagallo G; Bria E; Sperduti I; Oudard S;
    Clin Genitourin Cancer; 2020 Feb; 18(1):69-76.e4. PubMed ID: 31767448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
    Lu K
    Eur Urol; 2015 Dec; 68(6):e129-31. PubMed ID: 26318711
    [No Abstract]   [Full Text] [Related]  

  • 19. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
    Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
    Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
    Schrader AJ; Boegemann M; Ohlmann CH; Schnoeller TJ; Krabbe LM; Hajili T; Jentzmik F; Stoeckle M; Schrader M; Herrmann E; Cronauer MV
    Eur Urol; 2014 Jan; 65(1):30-6. PubMed ID: 23849416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.